Mesoblast Limited (MESO)Healthcare | Biotechnology | Melbourne, Australia | NasdaqGS
13.79 USD
-0.11
(-0.756%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 13.79 |
Hot Take ↕ | Oct. 10, 2026, 9:57 a.m. EDT
Mesoblast presents a classic biotech dilemma: a company with a massive catalyst potential (chronic low back pain commercialization) is currently punished by the market for its cash burn and lack of profitability. Fundamentally, the business is not deteriorating; in fact, the multi-year trajectory shows a net gain of over 100%, driven by a massive rebound in 2024 and 2025. However, the balance sheet is fragile, with free cash flow in the negative millions and a debt-to-equity ratio that warrants caution. The short-term outlook is bearish due to aggressive selling pressure and a lack of immediate earnings visibility, keeping the near-term rating low. Long-term, the asset is a speculative hold rather than a core investment; while the pipeline is promising, the path to profitability is steep and the valuation multiples are high relative to current revenues. The absence of a dividend reflects its growth-stage nature, but investors must be prepared for significant volatility as the company navigates its commercialization phase. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.060336 |
| AutoETS | 0.060412 |
| MSTL | 0.061431 |
| AutoTheta | 0.061562 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.250 |
| Excess Kurtosis | -1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.402 |
| Revenue per Share | 0.93 |
| Market Cap | 1,790,698,752 |
| Forward P/E | 30.31 |
| Beta | 0.86 |
| Profit Margins | -47.82% |
| Website | https://www.mesoblast.com |
As of Oct. 10, 2026, 9:57 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes significantly below the current price (e.g., $12, $14), while call activity remains sparse and concentrated at distant strikes ($19-$25). The imbalance suggests a fear of further downside rather than a bullish breakout, despite the company's recent price recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22562677 |
| Address1 | 55 Collins Street |
| Address2 | Level 38 |
| All Time High | 106.34 |
| All Time Low | 1.61 |
| Ask | 17.71 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 244,240 |
| Average Daily Volume3 Month | 227,721 |
| Average Volume | 227,721 |
| Average Volume10Days | 244,240 |
| Beta | 0.859 |
| Bid | 9.98 |
| Bid Size | 2 |
| Book Value | 4.38 |
| City | Melbourne |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.79 |
| Current Ratio | 2.435 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 13.95 |
| Day Low | 13.68 |
| Debt To Equity | 22.402 |
| Display Name | Mesoblast |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,787,783,400 |
| Earnings Call Timestamp Start | 1,787,783,400 |
| Earnings Timestamp | 1,787,774,400 |
| Earnings Timestamp End | 1,787,774,400 |
| Earnings Timestamp Start | 1,787,774,400 |
| Ebitda | -44,605,000 |
| Ebitda Margins | -0.37094003 |
| Enterprise To Ebitda | -40.764 |
| Enterprise To Revenue | 15.121 |
| Enterprise Value | 1,818,289,536 |
| Eps Current Year | -0.055 |
| Eps Forward | 0.455 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 3 9639 6030 |
| Fifty Day Average | 15.7142 |
| Fifty Day Average Change | -1.9242 |
| Fifty Day Average Change Percent | -0.12244976 |
| Fifty Two Week Change Percent | -22.562677 |
| Fifty Two Week High | 21.5 |
| Fifty Two Week High Change | -7.71 |
| Fifty Two Week High Change Percent | -0.35860464 |
| Fifty Two Week Low | 13.05 |
| Fifty Two Week Low Change | 0.7399998 |
| Fifty Two Week Low Change Percent | 0.05670496 |
| Fifty Two Week Range | 13.05 - 21.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,263,997,800,000 |
| Float Shares | 86,109,641 |
| Forward Eps | 0.455 |
| Forward P E | 30.307692 |
| Free Cashflow | -51,976,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 108 |
| Fullday Change | -0.105000496 |
| Fullday Change Percent | -0.755671 |
| Fullday Price | 13.79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.80019 |
| Gross Profits | 96,222,912 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.57382 |
| Held Percent Institutions | 0.03273 |
| Implied Shares Outstanding | 129,854,878 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,704,844,800 |
| Last Split Factor | 1:2 |
| Long Business Summary | Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. |
| Long Name | Mesoblast Limited |
| Market | us_market |
| Market Cap | 1,790,698,752 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_20356678 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -57,500,000 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 2,013,233,874 |
| Number Of Analyst Opinions | 2 |
| Open | 13.75 |
| Operating Cashflow | -43,830,000 |
| Operating Margins | -0.33278 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9639 6036 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.79 |
| Post Market Time | 1,792,010,169 |
| Previous Close | 13.895 |
| Price Eps Current Year | -250.72728 |
| Price Hint | 2 |
| Price To Book | 3.1484017 |
| Price To Sales Trailing12 Months | 14.891466 |
| Profit Margins | -0.47817 |
| Quick Ratio | 1.98 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.105 |
| Regular Market Change Percent | -0.755671 |
| Regular Market Day High | 13.95 |
| Regular Market Day Low | 13.68 |
| Regular Market Day Range | 13.68 - 13.95 |
| Regular Market Open | 13.75 |
| Regular Market Previous Close | 13.895 |
| Regular Market Price | 13.79 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 225,551 |
| Return On Assets | -0.04112 |
| Return On Equity | -0.09864 |
| Revenue Growth | 3.907 |
| Revenue Per Share | 0.93 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,854,878 |
| Shares Percent Shares Out | 0.0254 |
| Shares Short | 3,304,378 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,160,697 |
| Short Name | Mesoblast Limited |
| Short Percent Of Float | 0.0348 |
| Short Ratio | 17.02 |
| Source Interval | 15 |
| State | VIC |
| Symbol | MESO |
| Target High Price | 39.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 37.0 |
| Target Median Price | 37.0 |
| Total Cash | 102,914,000 |
| Total Cash Per Share | 0.791 |
| Total Debt | 127,334,000 |
| Total Revenue | 120,250,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.7685 |
| Two Hundred Day Average Change | -1.9785004 |
| Two Hundred Day Average Change Percent | -0.1254717 |
| Type Disp | Equity |
| Volume | 225,551 |
| Website | https://www.mesoblast.com |
| Zip | 3,000 |